IQ EQ FUND MANAGEMENT IRELAND Ltd Sells 2,955 Shares of IQVIA Holdings Inc. $IQV

IQ EQ FUND MANAGEMENT IRELAND Ltd reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 60.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,919 shares of the medical research company’s stock after selling 2,955 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in IQVIA were worth $364,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Waterloo Capital L.P. bought a new stake in IQVIA during the third quarter worth about $206,000. Bessemer Group Inc. lifted its position in IQVIA by 69.8% in the 3rd quarter. Bessemer Group Inc. now owns 1,948 shares of the medical research company’s stock worth $371,000 after buying an additional 801 shares during the last quarter. Savant Capital LLC boosted its stake in IQVIA by 6.6% in the third quarter. Savant Capital LLC now owns 21,941 shares of the medical research company’s stock worth $4,167,000 after buying an additional 1,367 shares in the last quarter. Hantz Financial Services Inc. grew its position in IQVIA by 92.0% during the third quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 115 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in shares of IQVIA by 2.3% during the third quarter. Envestnet Asset Management Inc. now owns 648,027 shares of the medical research company’s stock worth $123,086,000 after acquiring an additional 14,765 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $187.50 on Friday. The company has a market cap of $31.93 billion, a PE ratio of 23.85, a P/E/G ratio of 1.90 and a beta of 1.37. The business has a 50 day moving average of $228.03 and a 200 day moving average of $209.77. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a quick ratio of 0.70, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on IQV shares. Truist Financial lifted their target price on shares of IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Robert W. Baird set a $258.00 target price on IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Barclays reduced their price target on IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Friday. BMO Capital Markets set a $250.00 price objective on IQVIA in a research note on Friday. Finally, Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $241.75.

Key Headlines Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.